GlaxoSmithKline PLC — Regulatory Filings 2021

Feb 19, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2021

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the ' Company ')

Conditional Share Awards and Shares withheld or sold to meet tax liabilities

This notification sets out details of the vesting of awards made in 2018 under the GlaxoSmithKline Share Value Plan and the subsequent sale of Ordinary Shares to meet tax liabilities arising on the vesting. The awards, which were conditional on continued employment with the GlaxoSmithKline group, vested on 15 February 2021.

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms D Conrad | |
| --- | --- | --- | --- |
| b) | Position/status | SVP,
Human Resources | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The vesting of Ordinary Shares awarded in 2018 under the Company's
Share Value Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 10,050 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms D Conrad | |
| --- | --- | --- | --- |
| b) | Position/status | SVP,
Human Resources | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Following the vesting of Ordinary Shares awarded in 2018 under the
Company's Share Value Plan, Ms Conrad received a cash amount of
£127,452.09 (less applicable tax withholding) which is equal
to the market value of the number of Ordinary Shares which would
otherwise have been transferred to her. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £12.6818 | 10,050 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-17 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms S Jackson | |
| --- | --- | --- | --- |
| b) | Position/status | SVP,
Global Communications & CEO Office | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The vesting of Ordinary Shares awarded in 2018 under the Company's
Share Value Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 11,060 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms S Jackson | |
| --- | --- | --- | --- |
| b) | Position/status | SVP,
Global Communications & CEO Office | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2018 under the Company's Share Value
Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £12.6818 | 5,199 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D Jackson | |
| --- | --- | --- | --- |
| b) | Position/status | PCA of
Ms S Jackson (SVP, Global Communications & CEO
Office) | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The vesting of Ordinary Shares awarded in 2018 under the Company's
Share Value Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 6,330 |
| d) | Aggregated
information | N/A
(single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D Jackson | |
| --- | --- | --- | --- |
| b) | Position/status | PCA of
Ms S Jackson (SVP, Global Communications & CEO
Office) | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2018 under the Company's Share Value
Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £12.6818 | 2,976 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms D Waterhouse | |
| --- | --- | --- | --- |
| b) | Position/status | CEO of
ViiV Healthcare | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The vesting of Ordinary Shares awarded in 2018 under the Company's
Share Value Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 15,160 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms D Waterhouse | |
| --- | --- | --- | --- |
| b) | Position/status | CEO of
ViiV Healthcare | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2018 under the Company's Share Value
Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £12.6818 | 7,126 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms V Whyte | |
| --- | --- | --- | --- |
| b) | Position/status | Company
Secretary | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The vesting of Ordinary Shares awarded in 2018 under the Company's
Share Value Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £0.00 | 11,060 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | N/A | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms V Whyte | |
| --- | --- | --- | --- |
| b) | Position/status | Company
Secretary | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2018 under the Company's Share Value
Plan. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £12.6818 | 5,199 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-02-15 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: February
19, 2021
By:/s/ VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break